Targeting Janus kinases in the treatment of autoimmune disease

Key Takeaways for GI Nurses

• JAK (Janus kinase) inhibitors, including Jak3-targeted agents developed from the foundational research described here, are increasingly used to treat inflammatory bowel disease (IBD), a condition frequently managed through endoscopic surveillance and intervention.
• Patients on JAK inhibitor therapy (e.g., tofacitinib, upadacitinib) require special pre-procedure screening for infection risk, as these medications suppress cytokine signaling pathways critical to immune defense.
• Understanding that JAK inhibitors block signaling for multiple cytokines (IL-2, IL-4, IL-7, IL-9, IL-15, IL-21) helps nurses anticipate a broader immunosuppressive effect compared to more targeted biologics, which may influence periprocedural risk assessment.
• As this drug class expands to treat overlapping autoimmune conditions (psoriatic arthritis, ankylosing spondylitis, atopic dermatitis) alongside IBD, GI nurses will increasingly encounter patients with complex, multi-system autoimmune histories requiring coordinated care.

Clinical Relevance

This foundational research into Jak3 kinase signaling underpins an entire class of oral immunomodulatory drugs now integrated into IBD treatment algorithms. For endoscopy nurses, this matters practically: patients on JAK inhibitors present unique pre-procedure considerations, including screening for latent infections (particularly herpes zoster, given known class-associated risk), reviewing complete blood counts for cytopenias, and confirming medication timing relative to colonoscopy or upper endoscopy scheduling. Nurses conducting pre-procedure phone assessments or in-person histories should be comfortable recognizing JAK inhibitor names and understanding why these patients may require additional infection-risk questions compared to those on conventional immunosuppressants.

From a unit operations standpoint, the growing use of JAK inhibitors in IBD management means endoscopy units will see more patients requiring surveillance colonoscopies for dysplasia, disease activity monitoring via ileocolonoscopy, and biopsy protocols to assess mucosal healing—a key endpoint increasingly used to gauge JAK inhibitor efficacy. Nurses assisting with these procedures should understand that mucosal healing assessment often drives treatment continuation decisions, making accurate biopsy labeling, tissue handling, and documentation especially important for these patients' longitudinal care.

This research also has professional development implications. As cytokine-targeted therapies proliferate across autoimmune conditions, GI nurses benefit from ongoing education about the mechanism of action distinctions between JAK inhibitors, biologics (anti-TNF, anti-integrin, anti-IL-12/23 agents), and traditional immunomodulators. This knowledge supports better patient education, more accurate symptom triage (distinguishing disease flare from medication side effect), and stronger interdisciplinary communication with gastroenterology and rheumatology teams managing shared patients.

Bottom Line

JAK inhibitors, born from decades of cytokine signaling research, are now a mainstay therapy for IBD and several overlapping autoimmune conditions—meaning GI nurses should be prepared to screen these patients carefully for infection risk before endoscopic procedures and understand that mucosal healing assessment via biopsy often guides ongoing treatment decisions for this growing patient population.